CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target […]
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1-year target […]
